The IMIDomics Precision Discovery Engine™ integrates and analyzes clinical, epidemiologic and biomolecular data, to target and discover new therapeutic possibilities.

Inspired by Patients

IMIDs - including conditions like systemic lupus, rheumatoid arthritis, Crohn’s disease and psoriasis - afflict millions of people, creating health challenges that too often limit patients’ opportunities and significantly reduce their quality of life. In most cases, these diseases are chronic, incurable and continue to evolve over time, presenting new challenges to patients.

Each year, billions of dollars are spent treating patients with these conditions. However, current treatments are limited, resulting in some patients experiencing side effects with existing treatments while others are unable to find any relief at all. In fact, there are no curative medicines for these patients. The demand for new, effective therapies is therefore very significant – and these medicines can only come from a better understanding of these uniquely challenging diseases.

Our story

IMIDomics’ work is powered by our Precision Discovery Engine. This advanced and highly-focused analytics solution is built upon 15 years of innovation, forging connections with IMID patients and their physicians, and collecting a wealth of data and samples. This foundational work enables IMIDomics to lead in the discovery and development of new IMID treatments.

  • 2006

    IMID Clinical Consortium led by VHIR

    Cross-sectional IMID Grant Awarded

  • 2007

    Establishment of the IMID-Biobank

  • 2009

    ISO 9001 Certification

  • 2010

    First Cohort Collected

  • 2010

    HudsonAlpha Institute for Biotechnology Partnership

  • 2012

    Longitudinal IMID cohort grant awarded

  • 2012 - ongoing

    Continued Cohort Collection and Analysis

  • 2015

  • 2015


  • 2016

    Celgene Collaboration

  • 2018

    Becton, Dickinson and Company Collaboration

  • 2019

    H2020 EU Framework Grant

  • 2020

    Gossamer and BMS collaborations

  • 2021

    Series A Financing

  • 2022

    Strategic investment from EVOTEC SE

  • 2022

    Bioèxit Award from CataloniaBio & HealthTech